Brian S. Barnett, MD

Cleveland Clinic Psychiatric Treatment Resistance Program, Cleveland Clinic, Cleveland, Ohio

  • 4Articles
  • 4.6KReads
  • 2023–2026Active
  • 26Collaborators

About

Brian S. Barnett, MD is affiliated with Cleveland Clinic Psychiatric Treatment Resistance Program, Cleveland Clinic, Cleveland, Ohio. Brian S. Barnett has authored or co-authored 4 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2023 and 2026. Their work focuses on Psychedelics, Psychiatry, Depression (MDD), Electroconvulsive Therapy, and Sleep.

Publications

PCC
Psychological Adverse Effects of Psychedelic Use
Rounds in the General Hospital

Psychological Adverse Effects of Psychedelic Use

June 25, 2026

This case-based review explores psychological adverse effects of psychedelic use, covering risk factors, trauma history, phenomenology, and evidence-based management strategies for clinicians.
, , , et al
PCC
Medical Complications of Psychedelics
Rounds in the General Hospital

Medical Complications of Psychedelics

June 23, 2026

This case-based review covers acute complications, drug interactions, and long-term safety across psilocybin, MDMA, ketamine, and ibogaine, with practical guidance for clinicians.
, , , et al
JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Coprescribing of Z-Drugs and Opioids During COVID-19
Original Research

Coprescribing of Z-Drugs and Opioids During COVID-19

September 11, 2023

Coprescribing of nonbenzodiazepine sedative-hypnotics, or “Z-drugs,” with opioids was more common among older patients, although the odds of coprescription among patients overall decreased over the COVID-19 lockdown period.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe